Latest News and Press Releases

The First Onsite Survey on Environmental and Public Risk Perception finds that concern about infectious disease and future pandemics isn high

PridCor secures global antiviral portfolio with Phase 2b and Phase 3 assets to advance treatments for Long COVID and chronic illness.

BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...

A Los Angeles Superior Court judge rejected secrecy attempts by Sterling Pathology and its owner Dr. Chang Yang to shield alleged COVID-19 phantom tests

PridCor Therapeutics advances its SHIELD Long COVID study with a peer-reviewed publication and FDA confirmation of IND exemption.

React19 launches “This Is Our Shot” to raise $1M for vaccine-injured Americans, after giving $1.4 Million in aid.

Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE...

TUSCALOOSA, Ala., Sept. 23, 2025 (GLOBE NEWSWIRE) -- PridCor Therapeutics today announced that Dr. David Putrino, principal investigator of the company’s SHIELD Study, participated in a national...

Washington, DC, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Link to ThinkCareBelieve's Operation Warp Speed Article:  https://thinkcarebelieve.blog/2025/09/07/how-operation-warp-speed-saved/ Link to...

PridCor reports Long COVID case series: combo of valacyclovir, celecoxib & Paxlovid® shows significant, lasting symptom improvement.